Showing results (171-180 of 253) with videos related to

Sort By:
Pageof 26
Diabetes Care|December 12, 2007
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec, William F Keane, Zhongxin Zhang, et al.
Diabetes|September 8, 2011
Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetesAnna Syreeni, Assam El-Osta, Carol Forsblom, et al.
European Heart Journal|March 23, 2011
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trialsFrank A Holtkamp, Dick de Zeeuw, Pieter A de Graeff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2003
Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibitionBirger Hesse, Christian Meyer, Flemming S Nielsen, et al.
Diabetologia|November 4, 2017
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trialJelena P Seferovic, Marc A Pfeffer, Brian Claggett, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 12, 2013
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)Hiddo J Lambers Heerspink, Misghina Weldegiorgis, Lesley A Inker, et al.
Hypertension (Dallas, Tex. : 1979)|June 3, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialYan Miao, Stefan A Ottenbros, Goos D Laverman, et al.
Diabetes, Obesity & Metabolism|July 11, 2018
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular riskNienke M A Idzerda, Frederik Persson, Michelle J Pena, et al.
Cardiovascular Diabetology|October 27, 2017
Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studiesStijn A Peeters, Lian Engelen, Jacqueline Buijs, et al.
Plos One|October 15, 2008
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized studySøren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, et al.
Pageof 26